RT Journal Article
SR Electronic
T1 7% hypertonic saline and hyaluronic acid and in the treatment of infants mild-moderate bronchiolitis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1717
VO 38
IS Suppl 55
A1 Raffaella Nenna
A1 Stefano Papasso
A1 Massimo Battaglia
A1 Daniela De Angelis
A1 Laura Petrarca
A1 Dani Felder
A1 Serena Salvadei
A1 Rosaria Berardi
A1 Micol Roberti
A1 Paola Papoff
A1 Corrado Moretti
A1 Fabio Midulla
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/1717.abstract
AB The treatment of bronchiolitis is only supportive. The aim of our study was to evaluate the efficacy of hypertonic saline and hyaluronic acid (HS-HA) given by inhalation, in infants hospitalized for mild-moderate bronchiolitis. In a double-blind placebo-controlled study, 42 infants (26 males) less than 6 months of age (median age 2 months) were enrolled and randomly assigned to receive either HS-HA (7% NaCl + 0.1% HA) (n:21) or normal saline (n:20) at a dose of 2.5 ml twice a day for three days. To all infants a clinical severity score was assigned at the admission and four times daily during the hospitalization. Main outcome measures of our study were: number of days of hospitalization and reduction of the severity score. No differences were observed between the two groups for sex, age and clinical severity score at the admission. One child interrupted the protocol in the study group and two in the placebo group. 21% of children in the study group and 11% in the placebo group had mild cough after the aerosol. No difference was observed between the two groups with regard to the number of days of hospitalization (placebo group: 3.5 days vs study group: 3.1 days, p=0.4) and to the clinical score reduction during the first three days of hospitalization (placebo group: 3.3 vs study group: 3.7, p=0.6). HS-HA is a safe but not effective therapy in treating infants hospitalized for mild-moderate bronchiolitis.